Assessing InnoCare Pharma (SEHK:9969) Valuation After Priority Review Milestone For Zurletrectinib

InnoCare Pharma (SEHK:9969) has drawn fresh attention after China’s drug regulator granted priority review to its next generation TRK inhibitor zurletrectinib for pediatric NTRK fusion solid tumors, alongside inclusion in the CDE’s SPARK Program.

See our latest analysis for InnoCare Pharma.

The priority review news comes after a mixed stretch for the shares. A 1-day share price return of 5.44% lifted the stock to HK$11.83, while the 30-day and 90-day share price returns of 7.87% and 17.10% declines contrast with a 1-year total shareholder return of 21.33%. This suggests that recent momentum has cooled even as longer term holders have still seen gains.

If this regulatory update has you looking across the sector, it could be a good moment to scan 120 healthcare AI stocks as another way to spot healthcare names linked to advanced treatment technologies.

With the shares well below analyst targets and trading at an implied discount to intrinsic value, yet backed by ongoing clinical and regulatory progress, you have to ask yourself: Is this a mispriced opportunity, or is the market already baking in future growth?

Most Popular Narrative: 41% Undervalued

With InnoCare Pharma last closing at HK$11.83 versus a narrative fair value of HK$20.04, the current pricing gap is hard to ignore, especially given the ambitious growth story behind that estimate.

The company has a strong pipeline with numerous drugs in late-stage development, including tafasitamab, zurletrectinib, and others, expecting approvals and launches in the next few years, which could significantly bolster future revenues.

Read the complete narrative.

It is worth asking what kind of revenue curve and margin lift could justify that gap to fair value. The narrative leans on rapid top line growth, sharply improving profitability, and a rich future earnings multiple. Investors may want to see exactly how those assumptions stack up.

Result: Fair Value of HK$20.04 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this hinges on heavy R&D spend and a handful of key drugs, so any setback in trials or weaker than expected uptake could quickly challenge the idea that the shares are 41% undervalued.

Find out about the key risks to this InnoCare Pharma narrative.

Another View: Market Ratio Sends A Different Signal

While the narrative fair value suggests InnoCare Pharma is 41% undervalued at HK$20.04, the P/S ratio paints a more cautious picture. The stock trades on 12.4x sales versus a Hong Kong Biotechs average of 13.4x, yet above its own fair ratio of 9.9x. This points to valuation risk if sentiment cools.

If the market eventually leans closer to that 9.9x fair ratio instead of the growth narrative, would today’s discount to fair value still look as appealing to you?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals here leave you undecided, take a moment to review the underlying numbers yourself. Then move quickly to shape your own view with 4 key rewards.

Ready For Your Next Investment Idea?

If this story has sharpened your thinking, do not stop here. Use the screener to quickly surface fresh ideas before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com